Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC-015 single-dose study in adults with lipid disorders (Part 2)
ISRCTN43870533Phase 2Not yet recruiting
- Sponsor
- BaseCure Therapeutics
- Start
- Jan 2027
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of BC-015 in hypercholesterolemia and dyslipidemia (3 arms), sponsored by BaseCure Therapeutics. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
BC-015
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on ISRCTN43870533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN43870533.